ArticlePloS one2026
Economic evaluation of the second-line regimen of liposome irinotecan (II) combined with 5-FU/LV versus placebo combined with 5-FU/LV for locally advanced or metastatic pancreatic ductal adenocarcinoma in China.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05074589 (A Randomized, Double-blind, Single-dummy, Parallel-controlled, Multicentre, Phase III Clinical Study of Irinotecan Hydrochloride Liposome in Combination With 5-FU/LV as Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based Therapy), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Double-blind, Single-dummy, Parallel-controlled, Multicentre, Phase III Clinical Study of Irinotecan Hydrochloride Liposome in Combination With 5-FU/LV as Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based Therapy
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe cost-effectiveness of liposome irinotecan (II) (HR070803) in combination with 5-fluorouracil and leucovorin as a treatment for patients with locally advanced or metastatic pancreatic ductal adenocarcinoma offering a potential new standard of care has not been established. Considering the high cost of liposome irinotecan (II), the aim of this study was to evaluate the economic value of liposome irinotecan (II) combined with 5-fluorouracil and leucovorin（5-FU/LV） versus placebo combined with 5-FU/LV for this indication from the perspective of the Chinese healthcare system.
methodsWe developed a three-state Markov model based on the trial: NCT05074589 to estimate lifetime costs, quality-adjusted life-years (QALYs), and incremental cost-effect ratios (ICERs) in terms of cost per QALY gained. The utility of health status and the disutility of adverse events were obtained from the published literature. Costs were obtained from local hospitals and published literature. Costs and outcomes were discounted at a discount rate of 5% per year. To assess the robustness of the model, univariate and probabilistic sensitivity analysis was performed.
resultsIn the base-case analysis, liposome irinotecan (II) regimen provided an additional 0.08 QALYs compared to the placebo regimen with an ICER of $310,418.81/ QALY gained, which indicates that the liposome irinotecan (II) regimen is not cost-effective at the $39,221.95/ QALY threshold. One-way sensitivity analyses showed that the model was most sensitive to the utility of PFS, the cost of liposome irinotecan (II), and the utility of PD. Probabilistic sensitivity analyses showed that the liposome irinotecan (II) regimen had a probability of 0 for having a cost effect at $39,221.95/ QALY. Price simulations show that the liposome irinotecan (II) option is cost-effective at a willingness-to-pay (WTP) of $39,221.95/QALY if the price of liposome irinotecan (II) is reduced to $2.93/mg (88.6% reduction).
conclusionsFrom the perspective of the Chinese healthcare system, liposome irinotecan (II) in combination with 5-FU/LV was less cost-effective than placebo in combination with 5-FU/LV for locally advanced or metastatic pancreatic ductal adenocarcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.